Courtney M. Quinlan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Courtney M. Quinlan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ignacio E. Tapia
Division of Pediatric Pulmonology, University of Miami Miller School of Medicine, Miami, FL
2 shared publications Emma Escobar
Biostatistical and Informatics Cores of the Clinical and Translation Research Center of Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
1 shared publicationFrank D Mentch
The Center for Applied Genomics, Children’s Hospital of Philadelphia , Philadelphia, PA, 19104 , USA
1 shared publicationGerardo A. Vazquez-Garcia
Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
1 shared publication- Hakon Hakonarson
The Center for Applied Genomics, Children’s Hospital of Philadelphia
1 shared publication - Hui-Qi Qu
The Center for Applied Genomics, Children’s Hospital of Philadelphia
1 shared publication
Latest Publications
- 29 July 2022
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 47 (3)
Identification of novel loci in obstructive sleep apnea in European American and African American children
To identify genetic susceptibility variants in pediatric obstructive sleep apnea in European American and African American children. A phenotyping algorithm using electronic medical records was developed to recruit cases with OSA and control subjects from the Center for Applied Genomics at Children’s Hospital of Philadelphia (CHOP.) Genome-wide association studies (GWAS) were performed in pediatric OSA cases and control subjects with European American (EA) and African American (AA) ancestry followed by meta-analysis and sex stratification. The algorithm accrued 1,486 subjects (46.3% European American, 53.7% African American). We identified genomic loci at 1p36.22 and 15q26.1 that associated with OSA risk in EA and AA, respectively. We also revealed a shared risk locus at 18p11.32 (rs114124196, P =1.72 ×10 -8) across EA and AA populations. Additionally, association at 1q43 (rs12754698) and 2p25.1 (rs72775219) was identified in the male-only analysis of EA children with OSA, while association at 8q21.11 (rs6472959), 11q24.3 (rs4370952) and 15q21.1 (rs149936782) was detected in the female-only analysis of EA children and association at 18p11.23 (rs9964029) was identified in the female-only analysis of African-American children. Moreover, the 18p11.32 locus was replicated in an EA cohort (rs114124196, P =8.8 ×10 -3). We report the first GWAS for pediatric OSA in European Americans and African Americans. Our results provide novel insights to the genetic underpins of pediatric OSA.
- 29 July 2022
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 47 (3)
Identification of novel loci in obstructive sleep apnea in European American and African American children
To identify genetic susceptibility variants in pediatric obstructive sleep apnea in European American and African American children. A phenotyping algorithm using electronic medical records was developed to recruit cases with OSA and control subjects from the Center for Applied Genomics at Children’s Hospital of Philadelphia (CHOP.) Genome-wide association studies (GWAS) were performed in pediatric OSA cases and control subjects with European American (EA) and African American (AA) ancestry followed by meta-analysis and sex stratification. The algorithm accrued 1,486 subjects (46.3% European American, 53.7% African American). We identified genomic loci at 1p36.22 and 15q26.1 that associated with OSA risk in EA and AA, respectively. We also revealed a shared risk locus at 18p11.32 (rs114124196, P =1.72 ×10 -8) across EA and AA populations. Additionally, association at 1q43 (rs12754698) and 2p25.1 (rs72775219) was identified in the male-only analysis of EA children with OSA, while association at 8q21.11 (rs6472959), 11q24.3 (rs4370952) and 15q21.1 (rs149936782) was detected in the female-only analysis of EA children and association at 18p11.23 (rs9964029) was identified in the female-only analysis of African-American children. Moreover, the 18p11.32 locus was replicated in an EA cohort (rs114124196, P =8.8 ×10 -3). We report the first GWAS for pediatric OSA in European Americans and African Americans. Our results provide novel insights to the genetic underpins of pediatric OSA.
- 19 August 2019
- Published by Wiley in Pediatric Pulmonology
- Vol. 54 (11) , 1676-1683
The role of polysomnography in tracheostomy decannulation of children with bronchopulmonary dysplasia
Background: Patients with bronchopulmonary dysplasia (BPD) may require tracheostomy for long‐term mechanical ventilation. Polysomnography (PSG) may predict successful decannulation in children, however it is unclear how this success compares with children without a PSG. To better evaluate this role, we compared decannulation outcomes between tracheostomy‐dependent children with BPD who underwent PSG before decannulation to those who did not.Methods: This is a retrospective cohort study between 1 January 2007 and 1 June 2017 of tracheostomy‐dependent children with BPD who were clinically considered for decannulation. Patient demographics, PSG results, and medical comorbidities were abstracted from medical records and compared between groups. Decannulation outcomes were compared between children with BPD who underwent PSG before decannulation and those who did not.Results: One hundred twenty‐five patients with BPD were considered for tracheostomy decannulation. Forty‐six (37%) had a pre‐decannulation PSG while 79 (63%) did not. Nineteen (41%) patients did not undergo decannulation within 6 months of the PSG. One (3%) patient with pre‐decannulation PSG failed decannulation. Four (5%) patients without pre‐decannulation PSG failed decannulation. Nineteen patients with PSG and no decannulation had significantly higher obstructive apnea‐hypopnea index (OAHI) (13.62 vs 2.68 events per hour, P = 0.004), higher end‐tidal CO 2 max (52.84 vs 48.03 mm Hg, P = 0.035), and were older at PSG (median age, 6.04 vs 4.04 years, P = 0.008).Conclusions: While successful decannulation can be achieved without a PSG in some patients, PSG is a valuable tool to identify BPD patients undergoing clinical evaluation for decannulation who would benefit from treatment of OSA before decannulation.
- 19 August 2019
- Published by Wiley in Pediatric Pulmonology
- Vol. 54 (11) , 1676-1683
The role of polysomnography in tracheostomy decannulation of children with bronchopulmonary dysplasia
Background: Patients with bronchopulmonary dysplasia (BPD) may require tracheostomy for long‐term mechanical ventilation. Polysomnography (PSG) may predict successful decannulation in children, however it is unclear how this success compares with children without a PSG. To better evaluate this role, we compared decannulation outcomes between tracheostomy‐dependent children with BPD who underwent PSG before decannulation to those who did not.Methods: This is a retrospective cohort study between 1 January 2007 and 1 June 2017 of tracheostomy‐dependent children with BPD who were clinically considered for decannulation. Patient demographics, PSG results, and medical comorbidities were abstracted from medical records and compared between groups. Decannulation outcomes were compared between children with BPD who underwent PSG before decannulation and those who did not.Results: One hundred twenty‐five patients with BPD were considered for tracheostomy decannulation. Forty‐six (37%) had a pre‐decannulation PSG while 79 (63%) did not. Nineteen (41%) patients did not undergo decannulation within 6 months of the PSG. One (3%) patient with pre‐decannulation PSG failed decannulation. Four (5%) patients without pre‐decannulation PSG failed decannulation. Nineteen patients with PSG and no decannulation had significantly higher obstructive apnea‐hypopnea index (OAHI) (13.62 vs 2.68 events per hour, P = 0.004), higher end‐tidal CO 2 max (52.84 vs 48.03 mm Hg, P = 0.035), and were older at PSG (median age, 6.04 vs 4.04 years, P = 0.008).Conclusions: While successful decannulation can be achieved without a PSG in some patients, PSG is a valuable tool to identify BPD patients undergoing clinical evaluation for decannulation who would benefit from treatment of OSA before decannulation.
- 1 July 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (1) , 98-100
Inhaled Corticosteroids for the Prevention of Bronchopulmonary Dysplasia and Complications of Prematurity
- 1 July 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (1) , 98-100
Inhaled Corticosteroids for the Prevention of Bronchopulmonary Dysplasia and Complications of Prematurity
- 13 June 2019
- Published by Wiley in Pediatric Pulmonology
- Vol. 54 (10) , 1501-1507
Pediatric pulmonology year in review 2018: Sleep medicine
Pediatric Pulmonology publishes original research, case reports, and review articles on topics related to a wide range of children's respiratory disorders. In this article (Part 4 of a five‐part series), we summarize the past year's publications in sleep medicine, in the context of selected literature in this area from other journals. Articles are highlighted on topics including infant sleep, diagnosis, and treatment of obstructive sleep apnea, and sleep disorders in chronic disease.
- 13 June 2019
- Published by Wiley in Pediatric Pulmonology
- Vol. 54 (10) , 1501-1507
Pediatric pulmonology year in review 2018: Sleep medicine
Pediatric Pulmonology publishes original research, case reports, and review articles on topics related to a wide range of children's respiratory disorders. In this article (Part 4 of a five‐part series), we summarize the past year's publications in sleep medicine, in the context of selected literature in this area from other journals. Articles are highlighted on topics including infant sleep, diagnosis, and treatment of obstructive sleep apnea, and sleep disorders in chronic disease.